Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

Abstract

Our findings add support to the growing literature that TZD treatment is associated with an increased risk of fractures in both men and women, that effects of rosiglitazone and pioglitazone are similar and that fracture risk is increased even in younger women.